• S&P 500: 1,339.73
  • Change: -0.90%
$7.74 -0.02 (-0.26%)
2/10/2012 3:15 PM

Raptor Pharmaceuticals Corp. (NASDAQ:RPTP)

CAPS Rating: 2 out of 5

Current Price $7.74 Mkt Cap $267.77M
Open $7.70 P/E Ratio 0.00
Prev. Close $7.76 Div. (Yield) N/A (N/A)
Daily Range $7.66 - $7.77 Volume 140,825
52-Wk Range $3.10 - $7.90 Avg. Daily Vol. 0

News & Discussion Boards

Caps

How do you think RPTP will perform against the market?

You must Sign in to MSN Caps before you can make a call.

All Players

31 Outperform
4 Underperform
 

All-Star Players

7 Outperform
2 Underperform
 

Wall Street

5 Outperform
0 Underperform
 

Top RPTP Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.30)
Submitted April 26, 2011

Raptor Pharmaceuticals ... I'm not a fan. I've made my reasons for that clear before. But today the share price dipped to a new six-month low and I think it will go up from here in the short term. Traders may have become bored with the Raptor story… More

Add Comment | Reply | Report this Post

zzlangerhans (99.30)
Submitted December 07, 2011

Raptor has sneakily crossed back above my red thumb threshold in the absence of new positive catalysts. The DR Cysteamine NDA won't be filed until Q1 2012 which means we won't be seeing any revenue numbers until at least 2013. I think the traders who… More

Add Comment | Reply | Report this Post
RPTP VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about RPTP.

Recs

2
Member Avatar zzlangerhans (99.30) Submitted: 12/7/2011 12:14:33 AM : Underperform Start Price: $5.65 RPTP Score: -31.11

Raptor has sneakily crossed back above my red thumb threshold in the absence of new positive catalysts. The DR Cysteamine NDA won't be filed until Q1 2012 which means we won't be seeing any revenue numbers until at least 2013. I think the traders who sold on positive phase III results had the right idea. DR Cysteamine is more likely to join Nuedexta and Krystexxa than Soliris and Cinryze. Meanwhile, we haven't heard much lately about DR Cysteamine for NASH and Huntington's, or Convivia.

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar bassman87 (< 20) Submitted: 11/22/2010 1:52:32 PM : Outperform Start Price: $3.59 RPTP Score: +103.86

Has a solid pipeline of products that should be advancing into phase 3 stage of FDA approval and beyond through the next 12 to 36 months.

Most notable of all its products currently in phase 2 stage of development, is the drug Convivia. It is the only known drug currently in development and existence, that treats the "Asian Flush" symptoms associated with the consumption of alcohol by those who have the ALDH2 deficiency. There is a potentially huge market for this, as 40-50% of the East Asian populations suffers from this disorder alone. Chances are you know someone who suffers from this, evident by the appearence of red flush or blotchy areas to the face and neck area, and sometimes all over the body.

Demand for this product could be very high as there are many medical(cancer risk) and social(public appearence) implications to having this disorder.

Report this Post Add Comment | Reply | Permalink
View All 2 Pitches »

Leaderboard

Find the members with the highest scoring picks in RPTP.

Score Leader

portefeuille2

portefeuille2 (99.80) Score: +140.27

The Score Leader is the player with the highest score across all their picks in RPTP.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
portefeuille2 99.80 4/27/2011 Outperform 3W $3.24 +139.51% -0.76% +140.27 0 Comment
heals07 65.76 10/27/2010 Outperform 5Y $3.36 +130.95% +13.57% +117.39 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Turtleread 34.94 5/13/2011 Outperform 5Y $3.73 +108.04% -0.84% +108.88 0 Comment
bassman87 < 20 11/22/2010 Outperform 3Y $3.59 +116.16% +12.30% +103.86 1 Comment
SDTrond 88.96 2/4/2011 Outperform 1Y $3.83 +102.61% +2.44% +100.17 0 Comment
Guyzer 20.68 5/16/2011 Outperform 3M $3.93 +97.46% +0.34% +97.11 0 Comment
bullcallspread 73.46 5/18/2011 Outperform 5Y $4.19 +85.20% +0.74% +84.47 0 Comment
pastorga 63.42 5/23/2011 Outperform NS $4.55 +70.55% +1.27% +69.28 0 Comment
Manustocker < 20 7/26/2011 Outperform 1Y $5.09 +52.46% +0.21% +52.25 0 Comment
guden 76.15 9/19/2011 Outperform 5Y $4.75 +63.37% +12.12% +51.25 0 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackOppenheimer 79.35 9/16/2011 Outperform NS $4.39 +76.77% +10.50% +66.27 0 Comment
TrackLadenburg 78.39 7/11/2011 Outperform NS $6.28 +23.57% +0.96% +22.61 0 Comment
TrackCanaccord 88.88 5/12/2011 Outperform NS $3.43 +126.24% +0.14% +126.10 0 Comment
trackglobalhunte 57.13 5/5/2011 Outperform NS $3.36 +130.95% -0.04% +131.00 0 Comment
TrackJMP 84.91 3/15/2011 Outperform NS $3.50 +121.71% +4.97% +116.75 0 Comment

Featured Broker Partners